Oragenics Inc

ASE:OGEN   3:27:02 PM EDT
0.54
0.00 (+0.61%)
Products

Oragenics Says FDA Supports Co’s Pre-IND Development Program For SARS-CoV-2 Vaccine

Published: 10/06/2020 11:44 GMT
Oragenics Inc (OGEN) - FDA Broadly Supports Oragenics’ Pre-ind Development Program for Its Sars-cov-2 Vaccine.
Oragenics - Re-affirms Plan to File Ind Application by End of 1q21, Begin Phase 1 Study in Early 2q21 for Terra Cov-2.
Oragenics - FDA Has Requested Additional Preclinical Animal Data for Inclusion in Ind Filing for Terra Cov-2.
Oragenics - FDA Plans to Provide Final Comments Upon Reviewing Additional Data, Co's Phase 1 Trial Protocol for Terra Cov-2.